Physician profile
Bruce E Lessin
NPI 1003973165
$6,855.62
in general payments reported to CMS, 2019-2025
35 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,299 · 2020: $663 · 2021: $910 · 2022: $978 · 2023: $1,465 · 2024: $470 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,005.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $853.29 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $789.00 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $550.19 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.19 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $354.37 | 2019-2024 | |
| Abbvie INC. | $340.15 | 2019-2024 | |
| Amarin Pharma, INC. | $316.73 | 2019-2021 | |
| Glaxosmithkline, LLC. | $307.87 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Calliditas Therapeutics US INC. | $305.57 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $292.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $250.03 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $247.49 | 2019-2025 | Jynarque |
| Astellas Pharma US INC | $219.50 | 2019-2024 | Veozah |
| Lilly USA, LLC | $208.91 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Kowa Pharmaceuticals America, INC. | $198.89 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $193.92 | 2019 | |
| Exact Sciences Corporation | $174.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $139.41 | 2019-2023 | Farxiga |
| Esperion Therapeutics, INC. | $117.66 | 2020-2025 | Nexletol |
| Medicure Pharma INC. | $90.55 | 2021-2025 | Zypitamag |
| Genzyme Corporation | $46.93 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $43.62 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $39.62 | 2024-2025 | Gemtesa |
| Eisai INC. | $38.46 | 2021 | |
| Vistapharm, INC. | $33.07 | 2021 | |
| Boston Scientific Corporation | $31.18 | 2019 | |
| Vifor Pharma, INC. | $28.44 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $26.10 | 2023 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $23.40 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.63 | 2023 | Quviviq |
| Ibsa Pharma INC. | $18.65 | 2022 | |
| Medtronic, INC. | $14.05 | 2025 | Inceptiv |
| Allergan, INC. | $14.00 | 2020 | |
| Aytu Biopharma, INC. | $11.21 | 2019 | |
| Merck Sharp & Dohme LLC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Lessin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.